Patients with advanced solid malignancies that have progressed following standard therapy research hub

PHASE 1/2 STUDY OF PARG INHIBITOR ETX-19477 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES

This study is testing a new medicine, ETX-19477, for advanced cancers that haven't responded to usual treatments. It aims to see if the medicine is safe, what dose works best, and if it can shrink tumours or stop them from growing. It's an early-stage study.